title: Topical tacrolimus vs medium-dose ultraviolet A1 phototherapy in the treatment of atopic dermatitis - a preliminary study in relation to parameters of the epidermal barrier function and high-frequency ultrasonography.
abstract: BACKGROUND
  Atopic dermatitis (AD) is a chronic, relapsing skin disorder, which is characterized by intense pruritus, skin dryness and concomitant epidermal barrier dysfunction. The basic therapy involves the application of anti-inflammatory topical drugs like; glucocorticosteroids and calcineurin inhibitors. Phototherapy in AD is regarded as an additional form of treatment. The latest invention, ultraviolet A1-UVA1 phototherapy (340-400 nm), was introduced to the treatment of AD by Krutmann et al in 1992. It appears that the main mode of action of UVA1 phototherapy in AD is through activation of apoptosis of T lymphocytes. Additionally, new studies show that UVA1 can also inhibit the activity of calcineurin phosphatase, similarly to calcineurin inhibitors such as cyclosporin A or tacrolimus. The aim of this study is to, for the first time, compare the efficacy of medium dose UVA1 phototherapy and tacrolimus ointment in patients with moderate-severe AD.
  
  
  METHODS
  This study involved 20 AD patients. Half of the patients were treated with UVA1 phototherapy, while another 10 participants were treated with the application of tacrolimus ointment. The severity of the disease progress was assessed on the basis of EASI score (Eczema Area Severity Index). Moreover, the clinical condition of patients was assessed using non-invasive techniques such as measurement of transepidermal water loss - TEWL and skin capacitance, as well as high-frequency ultrasonography (20 MHz).
  
  
  RESULTS
  This study described above confirmed the beneficial influence of both therapies on the course of moderate-severe AD. Tacrolimus induced a greater reduction in TEWL, while phototherapy caused the reduction of subepidermal low echogenic band-SLEB within sites affected with pathological lesions.
  
  
  CONCLUSIONS
  Both tacrolimus and phototherapy treatment seemed to significantly reduce EASI.
authors.affiliation: Department and Clinic of Dermatology, Poznan University of Medical Sciences, Poznan, Poland. agnieszka.osmola@wp.pl.
authors.forename: A
authors.initials: A
authors.lastname: Osmola-Mańkowska
authors.forename: A
authors.initials: A
authors.lastname: Polańska
authors.forename: W
authors.initials: W
authors.lastname: Silny
authors.forename: R
authors.initials: R
authors.lastname: Żaba
authors.forename: Z
authors.initials: Z
authors.lastname: Adamski
authors.forename: A
authors.initials: A
authors.lastname: Dańczak-Pazdrowska
mesh_terms: D000287:Administration, Topical; D000328:Adult; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology / Q000528:radiation effects; D003876:Dermatitis, Atopic / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000528:radiation effects; D016559:Tacrolimus / Q000008:administration & dosage*; D016896:Treatment Outcome; D014463:Ultrasonography; D014467:Ultraviolet Therapy / Q000379:methods*
chemical_list: D016559:Tacrolimus